Paul Chaplin has worked at Bavarian Nordic since 1999 and has served as CEO since 2014. He will continue in the role for the remainder of the year, or until a successor has been appointed.
“Under his leadership, Bavarian Nordic has grown from a small research-based company with a single government customer to a large vaccine manufacturer with strong commercial operations in key markets. This growth has been made possible through strategic acquisition of travel vaccines, excellent tech transfer capability, and a successful commercial transformation of Bavarian Nordic”, the company writes in a press release.
BREAKING